ESR1 and breast cancer: In contrast, a high level of SDF-1 expression (in a cytoplasmic-dominant pattern) in BC cells seems to be a significant indicator of a better clinicopathological outcome, particularly in patients with ER-positive, HER-2-negative, and lower grade tumors [29].